NovaBridge Biosciences
NBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001778016
In the last 90 days, NovaBridge Biosciences insiders filed 0 open-market purchases and 4 sales; 49 institutions reported holding it in 13F filings for Q2 2026, worth $48.1M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding NovaBridge Biosciences changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 38 | 1 | 28 | −9 |
| Shares | 15.1M | 7.68K | 14.2M | −938.9K (−6.2%) |
| Value | $25.3M | $12.8K | $17.6M | −$7.72M (−30.5%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held NovaBridge Biosciences at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Freestone Capital Holdings, LLC | 10,000 | $12.4K | 0.00% |
| Tower Research Capital LLC (TRC) | 4,015 | $4.98K | 0.00% |
| BlackRock, Inc. | 1,438 | $1.78K | 0.00% |
| Simplex Trading, LLC | 417 | $0 | 0.00% |
Sold out (13)
Institutions that held NovaBridge Biosciences at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Gsa Capital Partners LLP | 272,193 | $455.0K |
| Exome Asset Management LLC | 271,400 | $453.2K |
| Bank of Montreal | 244,875 | $453.0K |
| State Street Corp | 102,961 | $171.9K |
| Invesco Ltd. | 57,933 | $96.7K |
| Donald L. Hagan, LLC | 30,000 | $50.1K |
| Marshall Wace, LLP | 14,064 | $23.5K |
| UBS Group AG | 12,514 | $20.9K |
| Qube Research & Technologies Ltd | 2,565 | $4.28K |
| Frazier Financial Advisors, LLC | 515 | $861 |
| Catalyst Funds Management Pty Ltd | 90 | $150 |
| GAMMA Investing LLC | 63 | $105 |
| Royal Bank of Canada | 145 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held NovaBridge Biosciences at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 7,684 | $12.8K |